References 1. De Rosa SC, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000 Oct;30(10):841-2. [PMID: 11029607]. 2. Atkuri KR, Mantovani JJ, Herzenberg LA, et al. N-Acetylcysteine -a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007 Aug;7(4):355-9. Review. [PMID: 17602868]. 3. White AC, Thannickal VJ, Fanburg BL. Glutathione deficiency in human disease. J Nutr Biochem. 1994;5:218-26.http://www. sciencedirect.com/science/article/pii/0955286394900396 Updated January 27, 2003. Accessed February 27, 2012. 4. Pace GW, Leaf CD. The role of oxidative stress in HIV Disease. Free Rad Biol Med. 1995;19:523-8. [PMID: 7590404]. 5. Favier A, Sappey C, Leclerc P, et al. Antioxidant status and lipid peroxidation in patients infected with HIV. Chem Biol Interact. 1994 Jun;91(2-3):165-80. Review. [PMID: 8194133]. 6. Nakamura H, Masutani H, Yodoi J. Redox imbalance and its control in HIV infection. Antioxid Redox Signal. 2002 Jun;4(3):455- 64. [PMID: 12215212]. 7. Roberts RL, Aroda VR, Ank BJ. N-acetylcysteine enhances antibody-dependent cellular toxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients. J Infect Dis. 1995 Dec;172(6):1492-502. [PMID: 7594708]. 8. Witschi A, et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43:667-9. [PMID: 1362956]. 9. De Rosa SC, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000 Oct;30(10):841-2. [PMID: 11029607]. 10. Atkuri KR, Mantovani JJ, Herzenberg LA, et al. N-Acetylcysteine -a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007 Aug;7(4):355-9. Review. [PMID: 17602868]. 11. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebocontrolled clinical trials. Clin Ther. 2000 Feb 22(2):209-21. [PMID: 10743980]. 12. Yalçin E, Altin F, Cinhüseyinoglue F, et al. N-acetylcysteine in chronic blepharitis. Cornea. 2002 Mar;21(2):164-8. [PMID: 11862087]. 13. Mirhosseini SJ, Forouzannia SK, Nasirian M, Ali-Hassan- Sayegh S. Saudi J Anaesth. N-acetylcysteine instead of theophylline in patients with COPD who are candidates for elective off-pump CABG surgery: Is it possible in cardiovascular surgery unit? Saudi Journal of Anaesthesia. 2013 Apr;7(2):151-4. doi: 10.4103/1658- 354X.114069. 14. Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, Loo CK, Chan MH. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013 Jul;144(1):106-18. doi: 10.1378/chest.12-2357. 15. Chalumeau M, Duijvestijn YC. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev. 2013 May 31;5:CD003124. doi: 10.1002/14651858.CD003124.pub4. 16. Jugg B, Fairhall S, Smith A, Rutter S, Mann T, Perrott R, Jenner J, Salguero J, Shute J, Sciuto AM. N-acetyl-L-cysteine protects against inhaled sulfur mustard poisoning in the large swine. Clin Toxicol (Phila). 2013 May;51(4):216-24. doi: 10.3109/15563650.2013.780208. Epub 2013 Apr 2. 17. Berk M, Malhi GS, Gray LJ, Dean OM. Trends Pharmacol Sci. 2013 Mar;34(3):167-77. doi: 10.1016/j.tips.2013.01.001. Epub 2013 Jan 29. The promise of N-acetylcysteine in neuropsychiatry. 18. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008 Sep;11(6):851-76. doi: 10.1017/ S1461145707008401. Epub 2008 Jan 21. 19. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW, Tirouvanziam R. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012 Jun 1;71(11):956-61. doi: 10.1016/j. biopsych.2012.01.014. Epub 2012 Feb 18.